^
    3d
    DUET-1: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Sotio Biotech Inc. | Trial completion date: Dec 2041 --> Dec 2042 | Trial primary completion date: Apr 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030
    12ms
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Sotio Biotech Inc. | Trial completion date: Jul 2039 --> Dec 2041 | Trial primary completion date: Jul 2024 --> Apr 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030
    over2years
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=98, Recruiting, SOTIO, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030
    over2years
    BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. (PubMed, PLoS One)
    Together, these results demonstrated that co-expression of GOT2 can substantially improve the overall antitumor activity of CAR T cells by inducing broad changes in cellular function and phenotype. These data show that BOXR1030 is an attractive approach to targeting select solid tumors. To this end, BOXR1030 will be explored in the clinic to assess safety, dose-finding, and preliminary efficacy (NCT05120271).
    Preclinical • Journal • IO biomarker
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    BOXR1030
    over2years
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=98, Not yet recruiting, SOTIO, LLC | Initiation date: Jan 2022 --> Apr 2022
    Trial initiation date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030
    3years
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=98, Not yet recruiting, SOTIO, LLC
    Clinical • New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    BOXR1030